Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
Study of rhASB in Patients With Mucopolysaccharidosis VI
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
You're leaving the BioMarin Clinical Trials website.
This will take you to BioMarin.com, our global corporate website. Some of the information on BioMarin.com is intended for U.S. audiences only.
Leave this website
Close
You’re leaving the BioMarin Clinical Trials website.
Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.
Leave this website
Close
